Assembly Biosciences, Inc.
NASDAQ:ASMB
14.21 (USD) • At close February 5, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Assembly Biosciences, Inc. |
Symbool | ASMB |
Munteenheid | USD |
Prijs | 14.21 |
Beurswaarde | 90,322,881 |
Dividendpercentage | 0% |
52-weken bereik | 9.84 - 19.93 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Jason A. Okazaki |
Website | https://www.assemblybio.com |
An error occurred while fetching data.
Over Assembly Biosciences, Inc.
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)